Drugs / CD19 or CD19-BCMA CAR-T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06548607 | Sep 2024 → Dec 2026 expected | Sjogren syndrome, anti-neutrophil antibody associated vasculitis, idiopathic inflammatory myopathy, systemic lupus erythematosus +1 | Nanjing Bioheng Biotech Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19 or CD19-BCMA CAR-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06548607 ↗ |
| Modality | Cell therapy | “CAR T-cell therapy” NCT06548607 ↗ |
| Route | Intravenous | “administered intravenously” NCT06548607 ↗ |
| Target | CD19 | “Targeted CD19 or CD19-BCMA CAR-T Therapy” NCT06548607 ↗ |